계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
SalioGen Therapeutics
company
About
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $115M
- Industries
- Biotechnology,Genetics,Life Science,Therapeutics
- Founded date
- Jan 1, 2020
- Number Of Employee
- 11 - 50
- Operating Status
- Active
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$115M
SalioGen Therapeutics has raised a total of
$115M
in funding over 2 rounds. Their latest funding was raised on
Jan 5, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 5, 2022 | Series B | $115M | 1 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
4
0
SalioGen Therapeutics has made 4 investments. Their most recent investment was on
Oct 7, 2021, when Kentik raised $40M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 7, 2021
Kentik
|
Series C | $40M | Cloud Data Services | — |
|
Aug 30, 2021
Eight Sleep
|
Series C | $86M | Consumer Electronics | — |
|
Aug 18, 2021
MobileCoin
|
Series B | $66M | Cryptocurrency | — |
|
Feb 16, 2021
Axiom Space
|
Series B | $130M | Advanced Materials | — |
Investors
Number of Lead Investors
Number of Investors
—
1
SalioGen Therapeutics is funded by 1 investors.
Retinal Degeneration Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Retinal Degeneration Fund
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
